Brief: Isofol Medical Q4 EPS at SEK -0.16
Feb 22 (Reuters) - Isofol Medical Q4 EPS SEK -0.16. * Q4 net income SEK -25.335 million * Q4 revenue SEK 1.857 million * During January, the board proposed the company to be liquidated, however the proposal did not achieve the required majority. Given this, Isofol's future will be decided in the first quarter of 2023-CEO
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million
Brief: Isofol Medical Announces Bfarm Approval Of Optimized Phase Ib/Ii Study Design
Brief: Isofol Gets Gross Proceeds Of SEK 18.9 Mln In Connection With Exercise Of Warrants And Guarantee Commitments
Brief: Isofol Secures License Rights For Arfolitixorin In Autism